Home > Journals > Minerva Pediatrics > Past Issues > Articles online first > Minerva Pediatrica 2021 Jan 13



To subscribe PROMO
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Pediatrica 2021 Jan 13

DOI: 10.23736/S0026-4946.20.05881-8


language: English

Pegylated interferon and ribavirin gone but not forgotten in the era of direct-acting antivirals

Magdalena PLUTA 1, 2 , Maria POKORSKA-ŚPIEWAK 1, 2, Małgorzata ANISZEWSKA 1, 2, Zbigniew LEWANDOWSKI 3, Barbara KOWALIK-MIKOŁAJEWSKA 1, 2, Magdalena MARCZYŃSKA 1, 2

1 Department of Children’s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland; 2 Hospital of Infectious Diseases, Warsaw, Poland; 3 Department of Epidemiology, Medical University of Warsaw, Warsaw, Poland


BACKGROUND: Therapy with pegylated interferon and ribavirin (PEG-IFN+RBV) for chronic hepatitis C (CHC) still remains the only option available for children in many Eurasian and European countries. Our aim was to evaluate the influence of host and viral factors on response to IFN-based therapy to optimize it for those in whom directly acting antivirals (DAA) are currently unavailable.
METHODS: Seventeen vertically infected, treatment naive children (10 male and 7 female) aged 5-16 years with CHC underwent a course of PEG-IFN+RBV. The end point was sustained virologic response (SVR). Host and virus factors were divided into pre- and ontreatment predictors of response to therapy.
RESULTS: Eleven patients obtained SVR (64%), 4 were nonresponders (23%), and 2 were relapsers (12%). Significant relationship was found between HCV RNA elimination and following variables: virus genotype and early virologic response (EVR) (p< .037, p< .029 respectively). Higher eradication rate was observed in patients infected with genotype 3 HCV (100% vs. 65% with genotype 1 or 4), and in those with undetectable HCV RNA by week 12 (88% vs. 66% with viremia). EVR was associated with SVR (83% vs. 0% in nonresponders; p< .004). C allele of IL28B rs12979860 was a predictor of EVR (p < .043). The SVR rates among CC, CT, and TT carriers were as follows: 75%, 67%, and 33%.
CONCLUSIONS: Detection of favourable HCV and IL28B genotype prior to commencement of PEG-IFN+RBV, and continuing it in patients with EVR is of major importance for those in whom DAA are still unavailable.

KEY WORDS: HCV in children; DAA; Pegylated interferon; SVR; Interleukin 28B

top of page